Request for Information Now Open
October 27-28, 2026 | San Juan, Puerto Rico
Registration opens in July. Sponsorship opportunities available now.
Collaborate on innovative manufacturing platforms and technologies that accelerate the development and manufacture of life-saving medicines and medical countermeasures, enhance national economic security, and support response to biothreats
Help companies de-risk the adoption and implementation of new technologies and approaches for development and manufacturing
Strengthen the U.S. economy by cultivating a world-leading biopharmaceutical workforce that meets the industry’s needs through novel training and education programs
Udit Batra, President & CEO, Waters
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
Deadline: July 21, 2026 | 5 pm ET
This Request for Information (RFI) invites interested parties to submit information for consideration in the “Equipment in Residence Program: An FDA/NIIMBL Collaboration” (abbreviated EiRP).
NIIMBL and the U.S. Food and Drug Administration (FDA) are collaborating on a program whereby new and emerging manufacturing-related and analytical measurement technologies can be made temporarily available to FDA staff for research and demonstration purposes. Technologies selected for EiRP will reside in an FDA lab for a period of at least three months and typically no more than twelve months.
Deadline: July 20, 2026 | 5 pm ET
NIIMBL is pleased to announce that applications are now open for 2027 NIIMBL eXperience regional lead organizations.
Regional leads will design and host a weeklong, all‑expenses‑paid summer program that introduces first‑ and second‑year college students to careers in biopharmaceutical manufacturing. Each site will deliver an immersive experience featuring hands‑on training, mentorship, facility tours, and direct engagement with industry professionals, helping to strengthen the future biopharma workforce.
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
Equipment in Residence: An FDA/NIIMBL Collaboration
Deadline: July 21, 2026 | 5 pm ET
This Request for Information (RFI) invites interested parties to submit information for consideration in the “Equipment in Residence Program: An FDA/NIIMBL Collaboration” (abbreviated EiRP).
NIIMBL and the U.S. Food and Drug Administration (FDA) are collaborating on a program whereby new and emerging manufacturing-related and analytical measurement technologies can be made temporarily available to FDA staff for research and demonstration purposes. Technologies selected for EiRP will reside in an FDA lab for a period of at least three months and typically no more than twelve months.
2027 NIIMBL eXperience Regional RFA
Deadline: July 20, 2026 | 5 pm ET
NIIMBL is pleased to announce that applications are now open for 2027 NIIMBL eXperience regional lead organizations.
Regional leads will design and host a weeklong, all‑expenses‑paid summer program that introduces first‑ and second‑year college students to careers in biopharmaceutical manufacturing. Each site will deliver an immersive experience featuring hands‑on training, mentorship, facility tours, and direct engagement with industry professionals, helping to strengthen the future biopharma workforce.
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Our members are stakeholders from across the biopharmaceutical manufacturing ecosystem, including large and small companies, academic institutions, and nonprofits.
Members have the opportunity to collectively revolutionize current biomanufacturing platforms, processes, and educational programs and share in the benefits of these transformative solutions.
The NIIMBL ecosystem’s collaborative efforts to accelerate innovative manufacturing technologies help to:
Biopharmaceuticals are medicines and medical countermeasures that save, sustain, and improve lives. They:
Mike Kress, Sr. Vice President Development Sciences and Clinical Supply,
Merck & Co., Inc.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.
